Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from NetraMark Holdings ( (TSE:AIAI) ) is now available.
NetraMark Holdings Inc. presented groundbreaking studies at the ISCTM conference, highlighting the effectiveness of their AI-driven approach, NetraAI, in improving clinical trial outcomes for major depressive disorder (MDD) and schizophrenia. The studies demonstrated that NetraAI significantly enhances patient stratification and model accuracy, outperforming traditional machine learning methods by identifying key variable combinations that refine trial design, thereby improving sensitivity and specificity.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in generative AI software, specializing in clinical trial analytics. The company focuses on leveraging advanced machine learning to enhance clinical trials, particularly in the areas of major depressive disorder and schizophrenia.
YTD Price Performance: 30.71%
Average Trading Volume: 14,639
Technical Sentiment Consensus Rating: Sell
Learn more about AIAI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue